A long time ago, our non-existent stroke leadership completely fucking failed at putting together magnetic nanoparticles delivering smaller loads of tPA resulting in much less chance of bleeds! Solving doctor reluctance.
We should have been using magnetic nanoparticles to deliver tPA for years.
Maybe this solution from March, 2015
Magnetic nanoparticles could stop blood clot-caused strokes
Or this from May, 2012
Future of med devices: Nanorobots in your blood stream
6 months ago, your competent? doctor started working on nanozymes, right? Oh, that's right, you DON'T have a functioning stroke doctor, do you?
The latest here:
Overcoming limitations of traditional CVD drugs
Cardiovascular diseases (CVDs) pose a significant threat to human health due to the high mortality and morbidity rates. Traditional drugs often have limited efficacy due to inherent constraints, such as low bioavailability and notable side effects.
As a highly regarded therapeutic strategy, nanotechnology offers new perspectives and means for treating CVDs. Nanozyme-based targeted therapeutic drugs specifically address the biological processes in areas affected by CVDs, thereby achieving precise treatment. Compared to traditional drugs, targeted nanozymes offer advantages, such as high efficiency, specificity, controllability, and fewer side effects, showing great efficacy in treating CVDs.
This paper explores the design strategies and mechanisms of nanozyme-based targeted therapy and introduces its application in key CVDs, such as ischemic stroke, myocardial infarction, and coronary heart disease. The challenges of introducing targeted nanozymes into clinical applications and the future development prospects in the treatment of CVDs are also discussed.
Liu, L. et. al. (2025) Targeted nanozyme-enabled treatment of cardiovascular diseases. Acta Materia Medica. doi.org/10.15212/AMM-2024-0046
No comments:
Post a Comment